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Abstract
Objectives. The aims of this study were to describe the clinical features of periodic fever, aphthous
stomatitis, pharyngitis and cervical adenitis (PFAPA) and identify distinct phenotypes in a large cohort
of patients from different countries.
Methods. We established a web-based multicentre cohort through an international collaboration within
the periodic fevers working party of the Pediatric Rheumatology European Society (PReS). The inclusion
criterion was a diagnosis of PFAPA given by an experienced paediatric rheumatologist participating in an
international working group on periodic fever syndromes.
Results. Of the 301 patients included from the 15 centres, 271 had pharyngitis, 236 cervical adenitis, 171
oral aphthosis and 132 with all three clinical features. A total of 228 patients presented with additional
symptoms (131 gastrointestinal symptoms, 86 arthralgias and/or myalgias, 36 skin rashes, 8 neurological
symptoms). Thirty-one patients had disease onset after 5 years and they reported more additional symp-
toms. A positive family history for recurrent fever or recurrent tonsillitis was found in 81 patients (26.9%).
Genetic testing for monogenic periodic fever syndromes was performed on 111 patients, who reported
fewer occurrences of oral aphthosis or additional symptoms. Twenty-four patients reported symptoms
(oral aphthosis and malaise) outside the flares. The CRP was >50 mg/l in the majority (131/190) of the
patients tested during the fever.
Conclusion. We describe the largest cohort of PFAPA patients presented so far. We confirm that PFAPA
may present with varied clinical manifestations and we show the limitations of the commonly used
diagnostic criteria. Based on detailed analysis of this cohort, a consensus definition of PFAPA with
better-defined criteria should be proposed.
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Introduction
Periodic fever, aphthous stomatitis, pharyngitis and
cervical adenitis (PFAPA) is a recurrent fever syndrome
diagnosed according to previously published criteria (sup-
plementary Table S1, available at Rheumatology Online)
[15] and clinician usually rely on these criteria. However,
because PFAPA is not a well-defined disease and there
are no specific confirmatory tests, the power of these
criteria remains limited.
Since the first description by Marshall in 1987 [6], 10
cohorts with >25 PFAPA patients per cohort (supplemen-
tary Table S2, available at Rheumatology Online) have
been published [1, 2, 5, 713] with different sets of
diagnostic criteria. The clinical manifestations differed in
frequency between the studies [14], suggesting that
these cohorts may not represent exactly the same popu-
lation of patients. In 2007 we created an international
cohort to describe the complete clinical and laboratory
spectrum of PFAPA syndrome and identify distinct
phenotypes.
Methods
We established a cohort (http://www.pfapa.net) with the
participation of 15 centres from eight countries (supple-
mentary Table S3, available at Rheumatology Online).
Only physicians with expertise in the field of recurrent
fever syndromes and PFAPA (publication or participation
in an international working group) were allowed to
participate.
The PFAPA patients were divided in complete cluster
(all three cardinal symptoms) and incomplete cluster (one
or two cardinal symptoms) groups. Exclusion of mono-
genic autoinflammatory (MAI) diseases was performed
according to the centres’ policy on clinical evaluation or
molecular analysis. The previously published diagnostic
criteria [1] were applied to our cohort and three distinct
phenotypes were described: complete vs incomplete
cluster, disease onset before vs after 5 years of age and
patients who underwent genetic testing or not.
Consecutive PFAPA patients were included using a
web-based form (Access, Microsoft Corporation,
Redmond, WA, USA) asking for demographic and clinical
information, laboratory investigations, treatment and out-
come. Only anonymous (de-identified) retrospective clin-
ical data were entered. The Commission cantonale (VD)
d’e´thique de la recherche sur l’eˆtre humain, CHUV,
Lausanne, Switzerland approved the study and the par-
ents/caregivers gave their informed consent according to
the local ethical regulations.
Statistical methods
Ninety-five per cent CIs were calculated based on the
Poisson distribution for the relative risk (RR) of reported
symptoms comparing subgroups of patients (three dis-
tinct phenotypes).
Results
From January 2007 to October 2009, 301 PFAPA patients
were included: 161 boys and 140 girls (1.15 male/1 fe-
male); median age at inclusion, 6.8 years (range 0.534);
median age at disease onset, 1.7 years (range 0.112);
median age at diagnosis, 4.0 years (range 0.832).
The median interval between fever attacks was 4 weeks
(range 112) and the median duration was 4 days (range
110). By definition, all patients presented with at least
one cardinal symptom (Table 1): pharyngitis (271, exuda-
tive 113), cervical adenitis (236, bilateral 205) and oral
aphthosis (171). Additional symptoms were reported by
228 patients (Table 2): abdominal pain, arthralgias, myal-
gias and headache were present during all or most flares
in the majority of the patients who reported them; the
other symptoms occurred only in some flares.
A positive family history was reported in 81/301 patients
[recurrent fever, 47; recurrent tonsillitis, 15; PFAPA, 11;
FMF, 8]. In the eight patients with a family history of
FMF, the clinical picture and genetic testing were non-
contributory for FMF. Parents originated mainly from
countries participating in the study (88% of the mothers
and 86% of the fathers; supplementary Table S4, avail-
able at Rheumatology Online), which corresponds to the
rate of foreigners living in European countries, suggesting
the absence of a specific ethnic background for PFAPA.
We are aware that the rates of foreign origin are only an
estimate of the rates of children with different ethnic
backgrounds.
According to the first of the current criteria [1], onset of
fever flares should occur before age 5 years (supplemen-
tary Fig. S1, available at Rheumatology Online), which was
not the case in 31 patients. Most of them (21/31) experi-
enced their first symptoms before age 6 years. In the 31
patients with later disease onset, pharyngitis, aphthae,
abdominal pain, diarrhoea, arthralgias and headache
were more frequent, and vomiting, nausea and cervical
adenitis less frequent (Tables 1 and 2).
Fifty-four patients (17.9%) reported only one cardinal
symptom, 115 (38.2%) two symptoms and 132 (43.9%)
all three symptoms; the latter, considered as a complete
PFAPA cluster, was more often found in patients with
disease onset after 5 years (Table 1). Patients with the
complete cluster were more often girls [73/132 (52%)]
than boys [59/132 (45%), RR = 1.88, 95% CI 1.6,
2.2, P< 0.001] (supplementary Fig. S2, available at
Rheumatology Online) and presented more frequently
with myalgias (24.4% vs 16.6%, RR = 1.63, 95% CI 1.25,
2.0, P< 0.01), arthralgias (34.6% vs 26.9%, RR = 1.44,
95% CI 1.1, 1.77, P< 0.05), osteoarticular symptoms
(46.2% vs 32.5%, RR = 1.78, 95% CI 1.45, 2.11,
P< 0.001), diarrhoea (22.5% vs 11.5%, RR = 2.23, 95%
CI 1.84, 2.62, P< 0.001), abdominal symptoms (66.4%
vs 53.6%, RR = 1.71, 95% CI 1.39, 2.04, P< 0.001) and
skin rash (19.4% vs 7.7%, RR = 2.87, 95% CI 2.45, 3.28,
P< 0.001).
In 145/301 patients, exclusion of MAI diseases was
done only on a clinical basis. Genetic testing was done
on 111 patients (36.9%) and was negative in 97 patients
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(supplementary Table S5, available at Rheumatology
Online). In some centres, mevalonic aciduria was mea-
sured during fever flares and mevalonate kinase (MVK)
deficiency (MKD) gene mutation analyses were performed
in patients with positive results. Genetic testing was more
frequently performed in patients with disease onset after
5 years [15/31 (48.4%), RR = 1.70, 95% CI 1.37, 2.03,
P< 0.001] than in patients with earlier disease onset
[96/270 (35.6%)]. We compared the clinical presentation
in patients who had genetic testing and patients without
genetic testing (supplementary Fig. S2, available at
Rheumatology Online).
In our cohort, 24 patients (8%) presented at least one
symptom between flares: malaise (4) and aphthous sto-
matitis (20). These patients did not present any other
symptoms, suggesting an alternative diagnosis such as
Behc¸et’s disease. All patients but one (height at 3 S.D.)
had normal growth.
CRP and neutrophil count showed a marked increase
during fever flares. CRP was >30 mg/l in 155 patients,
>50 mg/l in 131 and >100 mg/l in 77; outside the flare
the median value was 5 mg/l, and only 12 patients had a
level >10 mg/l. After a single dose of steroids (average
dose 1 mg/kg) at fever flare onset, resolution of the fever
occurred in 93/147 patients (63%), 46 (32%) were partially
improved and only 8 (5%) were non-responders.
Discussion
We report the largest cohort of PFAPA patients so far
described, aiming to describe particular PFAPA pheno-
types and to evaluate how expert paediatricians applied
the current diagnostic criteria on a large number of pa-
tients. The modified Marshall’s criteria remain highly un-
specific [15], and the lack of consensus on the PFAPA
definition is illustrated by differences in the criteria used
in previously published cohorts [16]. The diagnosis of
PFAPA is generally based on a number of variables (dra-
matic onset of attacks, lack of response to antibiotics,
repetitive presence of cardinal symptoms and prompt
response to steroids) that are much more complex than
the mere satisfaction of the current diagnostic criteria. For
these reasons, in order to avoid possible bias of selection,
we considered expert opinion as the gold standard.
Since the complete cluster (all three cardinal symptoms)
could represent the true typical PFAPA, we were surprised
to see more additional symptoms reported. We can
explain it by a better awareness of additional symptoms,
such as pain, presented by these children, or by the in-
crease in systemic symptoms in patients with more sys-
temic inflammation. Based on our findings, we cannot
challenge the current criteria, and conclude that
more than one cardinal symptom is needed for the diag-
nosis [15].
In our cohort we reported disease onset before 5 years
of age in 90% of patients [15]. There is no reason not to
believe that the 31 patients with later-onset disease have
PFAPA. A recently published observation of a series of
PFAPA patients with adult-age onset [17] challenges the
rationale for an age cut-off as a criterion. To record theT
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PFAPA syndrome cohort
exact date of disease onset may be difficult in young
children with recurrent infections, and because of the
long diagnostic delay (median 2.3 years). In our study,
late-onset PFAPA patients showed a higher frequency of
some symptoms, such as abdominal and osteoarticular
pain. A higher pain reporting capability in older children
can explain this difference, but also a selection bias, as
patients not meeting the age criterion would need to be
more convincing to the doctor. Since FMF and TNF re-
ceptorassociated periodic syndrome (TRAPS) may have
a later onset, genetic testing was more frequently per-
formed in this subgroup of patients. Our observation
shows similar clinical features in PFAPA patients with
later disease onset compared with other PFAPA patients,
suggesting that age is not a reason to exclude the diag-
nosis. In any case, in patients with disease onset after
5 years of age, we recommend intensifying the search
for other diagnoses, such as MAI, autoimmune disorders
and malignancies.
Because of the strict periodicity of fever attacks
described by Thomas et al. [1], only cyclic neutropenia
was considered as an exclusion in the criteria [15]. Since
a significant percentage of patients with MAI show regu-
larly recurrent attacks [7], they represent a relevant differ-
ential diagnosis [3, 8]. MKD has the highest degree of
clinical overlap with PFAPA [8], however, a PFAPA-like
phenotype can also be observed in children with FMF
and TRAPS [8, 18]. The patients who underwent genetic
testing presented more additional symptoms, which could
be a good reason for more frequent genetic testing. One
of our patients was affected by MKD and 14 patients
showed heterozygosis or polymorphisms in the MEFV or
MVK gene. In a recent study on 94 MEFV heterozygous
patients (mainly of Jewish or Arabic origin) with recurrent
fevers, only 4 patients presented a clear PFAPA pheno-
type [18]. We believe that the exclusion of MAI should be
included in a new version of the criteria. Recently a
diagnostic score based on the high frequency of specific
clinical manifestations was shown to be able to distinguish
those PFAPA-like patients at higher risk of carrying muta-
tion of genes associated with inherited periodic manifest-
ations [8].
In our cohort, the frequency of the different symptoms
was similar to previously published studies [3, 8]. In the
current diagnostic criteria, the description of the fever
episodes is rather vague and the characteristics of the
cardinal symptoms are not defined. The frequency and
duration of fever and a minimal number of episodes
were described but were not included in the original cri-
teria [1]. In our opinion, a more detailed description of
these variables in the criteria would help to better identify
PFAPA patients.
The presence of high CRP is uncommon in viral infec-
tions of the respiratory tract, another important differential
diagnosis of PFAPA. As reported previously [19], our
results showed high CRP values during PFAPA flares,
with normalisation between fever episodes in the vast ma-
jority of the patients, which strongly suggests PFAPA and
should be included in the criteria.
Symptoms (mainly aphthae) were reported outside
flares in 24 patients. In these patients a careful differential
diagnosis should be carried out, in particular Behc¸et’s
disease. A good response to steroids, as confirmed in
our cohort, may be used as an additional criterion for
diagnosis. However, other MAI such as MVK may also
respond well to this treatment.
Due to lack of consensus on precise classification cri-
teria and the absence of a definite diagnostic marker, our
study presents some limitations. We had to rely on the
expert interpretation of current PFAPA criteria as a gold
standard for the diagnosis. Every centre had its own
policy for exclusion of MAI, leading to great variability,
but there is currently no evidence on this and at the
time of collection no low-risk score was present.
TABLE 2 Frequency of different symptoms during flares among the 301 patients
Present Always Often Sometimes 55 years P-value RR (95% CI)
Abdominal symptoms 176 (59) 52 56 68 23 (74)
(at least one of below)
Pain 136 (45) 47 (15.8) 40 (13.5) 49 (16.5) 19 (61) <0.001 2.45 (2.13, 2.78)
Vomiting 53 (18) 3 (1.0) 16 (5.4) 34 (11.5) 2 (6) <0.001 0.31 (0, 0.71)
Nausea 32 (11) 2 11 19 1 (3) <0.01 0.28 (0, 0.75)
Diarrhoea 48 (16) 3 (1.0) 10 (3.4) 35 (11.9) 6 (19) <0.001 1.74 (1.32, 2.15)
Osteoarticular symptoms 118 (39) 23 48 47 16 (52)
(at least one of below)
Arthralgias 90 (30) 13 (4.4) 37 (12.5) 40 (13.4) 14 (45) <0.001 2.20 (1.85, 2.55)
Myalgias 56 (20) 12 23 21 8 (26) <0.01 1.59 (1.19, 1.99)
Arthritis 8 (3) 0 2 6 1 (3) ns (>0.50) 1.30 (0.51, 2.08)
Headache 85 (29) 19 35 31 12 (39) <0.05 1.72 (1.36, 2.07)
Skin rash 38 (13) 6 (2.0) 10 (3.4) 22 (7.4) 4 (13) ns (>0.50) 1.59 (1.19, 1.99)
Conjunctivitis 16 (5) 0 2 14 2 (6) ns (<0.30) 1.35 (0.75, 1.95)
Neurological symptoms 11 (4) 1 1 9 0 (0) ns (>0.50) 0.00 (0.69, 0.69)
Values are number of patients (%). ns: not significant.
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The periodicity of fever attacks was not recorded, and it
was not clearly required in the diagnostic criteria. Finally,
our cohort was recruited retrospectively to collect a rele-
vant number of patients.
With this study we report the largest cohort of PFAPA
patients published so far and we describe three distinct
phenotypes. Previous studies have suggested the low
specificity of the present PFAPA diagnostic criteria [8],
and we attempted to verify their possible pitfalls, identify
possible sources of misunderstanding and propose modi-
fications. Even if paediatricians are able to recognize
PFAPA patients, the absence of a validated classification
is problematic for further evaluation of treatment efficacy
and outcome. A classification system for PFAPA syndrome
based on a consensus among experts followed by a val-
idation process should be undertaken until we have a
better knowledge of the aetiology of PFAPA syndrome.
Rheumatology key messages
. The large cohort of patients describes different peri-
odic fever, aphthous stomatitis, pharyngitis and
cervical adenitis syndrome phenotypes.
. This study emphasizes the need for validated
classification criteria for periodic fever, aphthous
stomatitis, pharyngitis, cervical adenitis syndrome.
Disclosure statement: The authors have declared no
conflicts of interest.
Supplementary data
Supplementary data are available at Rheumatology Online.
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